ArticleFrontiers in medicine2026
Qiju Granule alleviates retinal damage in a mouse model of age-related macular degeneration.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Age-related macular degeneration (AMD) is the leading cause of visual loss in older people. Despite recent advances, the pathophysiology of AMD remains incompletely understood, and current therapies are limited. Qiju Granule is a traditional herbal formulation with therapeutic potential; however, its efficacy and mechanisms in AMD remain unclear. Objective: The aim of this study was to evaluate the protective effects of Qiju Granule in a mouse model of AMD and investigate potential underlying mechanisms. Methods: AMD-like retinal injury was induced in C57BL/6J mice by chronic light exposure combined with hydroquinone feeding. Retinal function and structure were assessed using electroretinography and histomorphological analyses. Retinal cell apoptosis and the expression of key angiogenic factors (VEGF and CD31) were assessed to explore underlying mechanisms. Results: Qiju Granule treatment significantly preserved retinal function, as reflected by improved electroretinographic responses, and maintained structural integrity of the retina and RPE layer. Mechanistically, Qiju Granule exerted potent anti-apoptotic effects, evidenced by a marked reduction in TUNEL-positive retinal cells. Furthermore, it downregulated VEGF and CD31 expression, indicating suppression of aberrant angiogenic signaling. Conclusion: Our findings identified a protective role of Qiju Granule in mitigating AMD-related retinal damage and suggested its potential as a therapeutic candidate to prevent progression to advanced AMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.